Streetbeat News

Products Services

SOBR

SOBR Safe, Inc. (NASDAQ:SOBR) has launched the sales of its alcohol monitoring wristband, SOBRsure, which is now available for purchase at www.SOBRstore.com. The wristband is intended for use by teen drivers, over-the-road trucking, outpatient alcohol treatment, and in establishing co-parenting confidence. The company has also partnered with Mothers Against Drunk Driving (MADD) to combat teen drunk driving.

Portfolio Pulse from Happy Mohamed

August 30, 2023 | 12:07 pm

CVKD

Cadrenal Therapeutics is expanding the evaluation of Tecarfarin for the treatment of patients with Antiphospholipid Syndrome who require chronic anticoagulation.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 12:07 pm

QMCO

Quantum Corporation (NASDAQ:QMCO) has announced new features in its end-to-end data platform to enhance hybrid cloud workflow. The new features include Quantum DXi Cloud Share, Quantum FlexSync 3, and Quantum ActiveScale Cold Replication. These features aim to increase operational agility, reduce business risk, and optimize costs across on-prem and public cloud resources. The new ActiveScale Cold Replication feature and FlexSync 3 are available immediately, while DXi Cloud Share is planned for release in Q4 2023.

Portfolio Pulse from Happy Mohamed

August 30, 2023 | 12:07 pm

CAH

Cardinal Health has launched the next-generation NTrainer System 2.0, a product designed to help premature and newborn infants develop oral coordination skills for independent feeding faster, potentially reducing their neonatal ICU stay.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 12:05 pm

BTCY

Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, reported a record $14 million annualized revenue run rate in August 2023, an increase of over eight percent from the previously announced $13 million run rate. The company's sales growth has been accelerated by better patient outcomes and substantial cost savings, as highlighted in its Corporate Impact Report. The company's Bioflux® cardiac monitoring device identified cardiac events in 4,960 of its 111,552 patients in 2022, leading to early intervention and significant cost savings.

Portfolio Pulse from Happy Mohamed

August 30, 2023 | 12:05 pm

CRMD

CorMedix Inc. (NASDAQ:CRMD) has been granted a new U.S. patent for the composition of a catheter lock solution, DefenCath, aimed at preventing infection and reduced blood flow in central venous catheters. The patent extends the company's intellectual property protection until April 15, 2042. The company also expects DefenCath to be eligible for 10.5 years of statutory marketing exclusivity in the U.S. upon potential FDA approval.

Portfolio Pulse from Happy Mohamed

August 30, 2023 | 12:04 pm

AAPL

BTCUSD

Apple Inc. is expected to unveil the iPhone 15 at the upcoming Wonderlust event on Sept. 12. The base model is priced at $799, the same as its predecessor, the iPhone 14. The article also compares the potential gains if the same amount was invested in Bitcoin on Sept. 9, 2022, when it was trading at $21,203. The investment would have grown to $1,030.11, a gain of 28.93%.

Portfolio Pulse from Mehab Qureshi

August 30, 2023 | 12:00 pm

SXTP

60 Degrees Pharmaceuticals has announced that the New Microbes and New Infections journal has published non-clinical study results showing that Tafenoquine exhibits broad-spectrum antifungal activity and decreases fungal burden in the lungs in an invasive pulmonary mouse.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:59 am

FGEN

FibroGen Inc's (NASDAQ:FGEN) investigational drug, pamrevlumab, failed to meet the primary endpoint in the Phase 3 LELANTOS-2 trial for Duchenne muscular dystrophy (DMD) patients. This follows the failure of the LELANTOS-1 trial in June and the ZEPHYRUS-1 trial for idiopathic pulmonary fibrosis. Despite the drug being generally safe and well tolerated, the company's shares fell by 22.3% in premarket trading.

Portfolio Pulse from Vandana Singh

August 30, 2023 | 11:42 am

ZLAB

The Center for Drug Evaluation of National Medical Products Administration has granted Breakthrough Therapy Designation to Zai Lab's Repotrectinib. The drug is intended for advanced solid tumors with NTRK gene fusion in patients who have progressed after TRK Tyrosine Kinase Inhibitor treatment.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 11:39 am